Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
119 hedge funds and large institutions have $640M invested in Eagle Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 36 reducing their positions, and 33 closing their positions.
151% more call options, than puts
Call options by funds: $39.6M | Put options by funds: $15.8M
17% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 36
11% less funds holding
Funds holding: 133 → 119 (-14)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
39% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 33
52% less capital invested
Capital invested by funds: $1.32B → $640M (-$682M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$49.6M |
| 2 |
HEC
Hudson Executive Capital
New York
|
+$26.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.6M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$13.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$45.2M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
-$11.8M |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$6.17M |
| 4 |
O
OppenheimerFunds
New York
|
-$6.1M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$4.31M |
EGRX Hedge Fund Activity: Q1 2016 in Review
119 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2016, worth a combined $640M — down 52% from $1.32B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EGRX and 20 opened new positions — a net loss of 13 holders — while 36 trimmed existing stakes and 42 added.
The largest buyer was Park West Asset Management, adding an estimated $49.6M. The largest seller was Consonance Capital Management, cutting an estimated $45.2M.
- 119 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2016, down from 133 in Q4 2015.
- Funds reported $640M of Eagle Pharmaceuticals, Inc. stock for Q1 2016, down 52% quarter-over-quarter.
- 20 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2016 and 33 closed out, a net change of -13 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2016 was Park West Asset Management, an estimated $49.6M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2016 was Consonance Capital Management, an estimated $45.2M sold.
Based on aggregated 13F filings for Q1 2016.